BioSpace News Archive

Immune-Onc Therapeutics, Inc. today announced the Company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 12:30 PM PST/3:30 PM EST.

Aardvark Therapeutics, Inc. proudly announces that it has received an invitation to present at the 40th annual J.P. Morgan Healthcare Conference on January 13th, 2022.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

Gameto today announced that it has raised a $20 million in Series A funding led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures.

Appointment expands leadership team and reflects growing strength of opportunities across the company’s portfolio, including Currax’s CX-101 program for smoking cessation.

Natus Medical Incorporated, a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced preliminary 2021 fourth quarter and full year revenue.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced an update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).

Cytokinetics, Incorporated announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021, as a material inducement to their employment.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030.